With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

SENS-401 is currently being evaluated in a Phase 2 clinical trial for SSNHL and Phase 2 ready for Cisplatin-Induced ototoxicity (CIO)

20190603 pipeline

 

Latest news

  • 02 Apr 2020

    Sensorion reports full-year 2019 financial results and business update Solid €30m cash position at year end and runway increased to beginning of Q3 2021. Read

  • 13 Mar 2020

    Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment. Read

Patient center

Corporate presentation